Advanced Bacteriocin-Based Antimicrobial Systems

Next-generation bacteriocin-based antimicrobial systems that selectively target Gram-negative bacteria, inducing cell lysis through targeted disruption of the peptidoglycan sacculus, providing a paradigm shift in antimicrobial therapy.

The original patent disclosed therapeutic bacteriocins for reducing microbial growth, but limitations in translocation and cargo domains hindered their effectiveness. The new inventive concept addresses these limitations by introducing advanced receptor-mediated translocation domains and cargo domains that selectively disrupt the peptidoglycan sacculus, enabling more targeted and efficient antimicrobial therapy.

The advanced bacteriocin-based antimicrobial systems comprise a bacteriocin-based entity with a receptor-mediated translocation domain that selectively targets Gram-negative bacteria, and a cargo domain that can disrupt the peptidoglycan sacculus of the bacteria, inducing cell lysis. The entity is capable of self-assembly into a nanoparticle for targeted delivery. The system further comprises a nanoparticle-based delivery vehicle for targeted delivery of the entity to the site of infection. This enables the treatment of bacterial infections, prevention of biofilm formation, and reduction of microbial growth.

The new claims introduce a paradigm shift in antimicrobial therapy by selectively targeting Gram-negative bacteria and disrupting the peptidoglycan sacculus, which is not addressed in the original patent. The inventive step lies in the advanced receptor-mediated translocation domains and cargo domains that enable targeted and efficient antimicrobial therapy.

Alternative embodiments of the inventive concept could include variations in the receptor-mediated translocation domain, cargo domain, and nanoparticle-based delivery vehicle to target different types of bacteria or infections. Additionally, the system could be adapted for use in agricultural or environmental applications.

The advanced bacteriocin-based antimicrobial systems have significant commercial potential in the pharmaceutical industry, particularly in the treatment of bacterial infections and prevention of biofilm formation. The market for antimicrobial therapies is growing, and this inventive concept addresses a significant unmet need in the field.